Media Articles Related to Zarontin (Ethosuximide)
Fycompa (perampanel) receives European MA for PGTC seizures in patients with idiopathic generalised epilepsy
Source: Epilepsy News From Medical News Today [2015.06.26]
The European Commission (EC) has today granted marketing authorisation approval for Fycompa® (perampanel), for use as a once-daily, adjunctive therapy for primary generalised tonic-clonic...
FDA Okays New Indication for Perampanel (Fycompa) in Epilepsy
Source: Medscape NeurologyHeadlines [2015.06.22]
Perampanel, already approved for focal seizures, is now indicated as adjunctive therapy for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
Neurostimulation in epilepsy: New techniques, new promises
Source: Epilepsy News From Medical News Today [2015.06.22]
"Despite the advent of new pharmacological treatments and the high success rate of many surgical treatments for epilepsy, a substantial number of patients do not become seizure-free or experience...
Participating in online health community may help people manage epilepsy
Source: Epilepsy News From Medical News Today [2015.06.18]
Participating in an online patient community may help people with epilepsy better manage the disease, according to a study published in the online issue of Neurology®, the medical journal of...
Online Community Helps People Manage Epilepsy
Source: MedicineNet Seizure Specialty [2015.06.18]
Title: Online Community Helps People Manage Epilepsy
Category: Health News
Created: 6/17/2015 12:00:00 AM
Last Editorial Review: 6/18/2015 12:00:00 AM
Published Studies Related to Zarontin (Ethosuximide)
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. [2010.03.04]
BACKGROUND: Childhood absence epilepsy, the most common pediatric epilepsy syndrome, is usually treated with ethosuximide, valproic acid, or lamotrigine. The most efficacious and tolerable initial empirical treatment has not been defined... CONCLUSIONS: Ethosuximide and valproic acid are more effective than lamotrigine in the treatment of childhood absence epilepsy. Ethosuximide is associated with fewer adverse attentional effects. (ClinicalTrials.gov number, NCT00088452.) 2010 Massachusetts Medical Society
Effect of intracranial administration of ethosuximide in rats with spontaneous or pentylenetetrazol-induced spike-wave discharges. [2011.07]
PURPOSE: Generalized absence seizures are characterized by bilateral spike-wave discharges (SWDs), particularly in the frontoparietal cortical region. In WAG/Rij and GAERS rats with absence epilepsy, recent evidence indicates that SWDs arise first from the lateral somatosensory cortex (LSC), that is, the cortical focus theory...
Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. [2010.08]
PURPOSE: Epilepsy is a heterogeneous syndrome characterized by recurrent, spontaneous seizures; continuous medication is, therefore, necessary, even after the seizures have long been suppressed with antiepileptic drug (AED) treatments. The most disturbing issue is the inability of AEDs to provide a persistent cure, because these compounds generally suppress the occurrence of epileptic seizures without necessarily having antiepileptogenic properties...
Ethosuximide converts ictogenic neurons initiating absence seizures into normal neurons in a genetic model. [2009.07]
Absence epilepsy is a form of generalized epilepsy commonly seen in children. The neuronal process by which ethosuximide (ETX), a first choice anti-absence drug, prevents absence seizures is still unresolved...
Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves. [2008.11]
The aim of this study was to characterize the interaction between tiagabine (TGB) and ethosuximide (ETS), two antiepileptic drugs, in pentylenetetrazole (PTZ)-induced clonic seizures in mice using isobolographic analysis. The nature of the interaction between the drugs administered in combination was ascertained by estimating plasma and brain concentrations of ETS and TGB using fluorescence polarization immunoassay (FPIA) and high-performance liquid chromatography (HPLC)...
Clinical Trials Related to Zarontin (Ethosuximide)
Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS). [Recruiting]
Pain remains the most debilitating symptom for adult patients suffering from complex
regional pain syndrome (CRPS). Most CRPS patients gain little to no relief from current
painkillers. The purpose of this study is to evaluate the efficacy and safety of
ethosuximide in search of much-needed adjunctive therapy to relieve the pain and suffering
associated with CRPS.
Chemotherapy Induced Painful Peripheral Neuropathy Ethosuximide (The CIN-E Study) [Recruiting]
This study is a drug trial of ethosuximide as a painkiller if you develop pain as a side
effect of chemotherapy. Ethosuximide will be compared against placebo (an inactive
substance) to test whether any response is a true effect of the drug, and not a 'placebo
Comparison of a Drug and Placebo in the Prevention of Migraine Headaches [Not yet recruiting]
The purpose of this study is to determine whether ethosuximide works better than placebo in
the prevention of episodic migraine among veterans.
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study [Active, not recruiting]
Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy [Recruiting]
This is an open randomized controlled study in children with mental retardation and
refractory epilepsy in which treatment with ketogenic diet (KD) is compared with treatment
with the antiepileptic drug (AED), not tried by the patient before, which we consider to be
the most appropriate AED for the patient.
Reports of Suspected Zarontin (Ethosuximide) Side Effects
Drug Ineffective (3),
Poor Quality Drug Administered (3),
Mycoplasma Infection (2),
Abdominal Discomfort (2),
Stevens-Johnson Syndrome (2),
Oral Infection (2),
Toxic Epidermal Necrolysis (2), more >>